Bruker introduces next version of its preclinical imaging software

Bruker has announced the launch of ParaVision® 360 Preclinical Imaging Software and AVANCE® NEO Systems with Advanced Multi-Receive Architecture for MRI.

ParaVision 360 facilitates convenient workflows with SOPs for MRI, and an integrated PET/MR workflow, from animal positioning to scan sequences, to processing and management.  This enables data accuracy and reproducibility, which gives consistent quantification to deliver a global discovery and validation process. The AVANCE NEO is a magnetic resonance console with a multi-channel architecture that can be configured for up to 24 transmit and receive MRI channels. It gives faster MRI control, improved dynamic range, scalability and flexibility.

Dr. Wulf-Ingo Jung, President of the Bruker BioSpin Preclinical Imaging division, said: “ParaVision 360 and the AVANCE NEO are new enabling platforms for seamless, multimodal preclinical imaging.  The PET/MR market is dynamic and fast growing, and we take pride in being a leading innovator with our full Field Of View (FOV) PET inserts and in-line systems, even for ultra-high field MRI.  These innovations will contribute to a better understanding of pathobiology, and to the development of new treatments for diseases like cancer, cardio-vascular or neuro-degenerative diseases.”

Dr. Tim Wokrina, Preclinical MRI Market Manager at Bruker said: “ParaVision 360 with AVANCE NEO set new standards in preclinical imaging.  We are excited by the unique dynamic shimming capability for a drastic improvement in sensitivity and specificity of metabolic imaging, and more accurate mapping of the structural and functional connectivity in neuroscience.  ParaVision 360 includes the unique IntraGateUTE method, which offers artefact-free images of the beating heart.  Cardiology researchers can achieve full heart coverage CINE measurement in less than 15 minutes in a small rodent, at least 8 times faster than with any other preclinical method. This is a milestone in cardiovascular preclinical research.”